# SPORE in Soft Tissue Sarcoma

> **NIH NIH P50** · SLOAN-KETTERING INST CAN RESEARCH · 2021 · $2,126,450

## Abstract

ABSTRACT
The long-term goal of the SPORE in Soft Tissue Sarcoma is to reduce the morbidity and mortality from
soft tissue sarcoma by developing therapies targeted to specific molecular, genetic, epigenetic, and
signaling pathway alterations or specific sarcoma type and subtype. To pursue this, we will focus our
efforts on 4 broad translational research objectives: 1. Define shared and type-specific molecular
mechanisms of sarcomagenesis to identify new rational therapeutic targets; 2. Define mechanisms of
resistance to targeted therapies; 3. Clinically validate new therapeutic targets and treatments in soft
tissue sarcoma patients and facilitate the development, recruitment, and application of clinical trials that
serve both the adult and pediatric populations; 4. Discover specific molecular alterations and new
biomarkers that predict outcome and response to targeted therapy. To achieve these goals, we have
marshaled an integrated, multidisciplinary group of basic and clinical investigators, all armed with a
unique resource, a clinicopathologic and outcomes database prospectively collected over a 35-year
period. This database now contains data for over 11,840 patients treated for soft tissue sarcoma at
MSKCC. The database is linked to an extensive sarcoma tissue/blood bank, which in turn is linked to an
extensive multi-platform molecular genetic and epigenetic dataset and a collection of primary sarcoma
cell lines and mouse xenograft/PDX models of human sarcoma. The SPORE is structured around 4
research projects, 4 cores, and career enhancement and developmental research programs. Each research
project focuses on three or more of the 4 broad translational research goals listed above. RP-1 (GIST
Resistance) aims to identify new therapeutic targets and develop new treatment strategies for imatinib-
resistant GIST, including strategies for the largely pediatric subset with SDH-deficient GIST. RP-2 (CDK4
Targeting) seeks to identify a pre-treatment biomarker predictive of prolonged clinical response to CDK4
inhibitor therapy and to find drugs that can be combined with CDK4 inhibition to synergistically
augment the senescence response. RP-3 (Oncogenic Pathways) seeks to determine the efficacy and
molecular effects of inhibitors of mTOR, PI3K, MEK, and oncogenic translation (eIF4A), alone and in
combination, in myxofibrosarcoma and undifferentiated pleomorphic sarcoma to develop new targeted
treatment strategies. RP-4 (Functional Genomic Screens) will perform CRISPR-based functional genomic
screens to uncover epigenetic and genetic vulnerabilities in synovial sarcoma with the aim of discovering
drug targets for preclinical and clinical evaluation.

## Key facts

- **NIH application ID:** 10247663
- **Project number:** 5P50CA217694-04
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** SAMUEL SINGER
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,126,450
- **Award type:** 5
- **Project period:** 2018-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10247663

## Citation

> US National Institutes of Health, RePORTER application 10247663, SPORE in Soft Tissue Sarcoma (5P50CA217694-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10247663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*